Global Gene Therapy Market – Size, Share, Opportunity, Trend, Forecast, Analysis 2020 – 2030

Market Overview:
The Global Gene Therapy Market was valued at USD 5,926.3 million in 2022 and it is poised to grow beyond USD 22,157.9 million by the end of 2028; registering a CAGR of 19.6% during the forecast period of 2023-2028.
Genes are composed of DNA that encodes necessary information for the synthesis of proteins that are vital for the human body to function optimally. Gene therapy is a technique in which DNA is introduced into a patient to treat genetic diseases. The new DNA contains a functioning gene to correct the effects of a disease, which causes mutations. Gene therapy is an experimental technique that uses genes to treat or prevent diseases. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery. Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under study to make sure that it will be safe and effective.

Market Impacting Factors:
The market for Gene Therapy is assessed to be reinforced by a vigorous item pipeline. The developing financing by key players is anticipated to make positive scenery for improvement in the coming years. Likewise, the raised event of target infections and creative medicine necessities is expected to prod the Gene Therapy Industry for the forecasted market.
Gene therapy involves repairing, repressing, or replacing dysfunctional genes that cause disease with the aim of reestablishing normal function. This therapy serves as a promising treatment option for some genetic diseases such as muscular dystrophy and cystic fibrosis as well as certain inherited disorders, cancer, and viral infections. In addition, it aids in drug development to identify the right target and approach, thereby addressing the root cause of severe diseases. In certain disorders where known genetic mutations lead to deficient or nonfunctional protein production, gene therapy can fix the underlying defect and provide a path to produce the functional protein. In addition, the risk of gene therapy is less, as a new gene introduced will integrate itself into the genome of the patient and continue functioning without hampering the operations of other genes. Hence, these aforementioned factors help in increasing the global gene therapy market share.
The different components driving the Gene Therapy market incorporate the rising occurrence of malignancy and different sicknesses, developing a quality treatment pipeline and expanding subsidizing for the Gene Therapy research. But the significant expense related to Gene Therapy and not many repayment options is considered as a challenging factor in the Gene Therapy market. Hence this challenge must be effectively dealt with in order to enhance the growth of the Gene Therapy Industry. An increment in subsidizing and venture for progressions in quality treatments are required to give rewarding development freedoms to the key players. It is considered an effective opportunity that is driving the growth of the Gene Therapy market. Moreover, organizations are occupied with key unions to support their contributions in the space, which is expected to heighten the market rivalry during the estimated time frame.

Geographic Analysis:
The North America regional market led the industry in 2020 with a revenue share of more than 55% and will grow further at the fastest CAGR over the forecast years. On account of a strong regulatory framework for promoting the development of cellular therapy and the presence of a substantial number of biopharma companies, several government agencies are investing in the region. This, in turn, is driving the growth of the regional market.
The presence of centers and institutes engaged in R&D on gene therapies is likely to continue driving the market in North America. Several companies from regions, such as Europe, which have received EU approvals, are planning to receive FDA approvals over. For example, post-EU approval of bluebird Bio’s Zynteglo (formerly LentiGlobin) in June 2019, the company is planning to file for an FDA approval.

Competitive Scenario:
Major players operating in the global Gene Therapy market include REGENXBIO, Inc., Oxford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corporation, F. Hoffmann-La Roche Ltd., Bluebird Bio, Inc., Novartis AG, Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics), UniQure N.V., Shire Plc, Cellectis S.A., Sangamo Therapeutics, Inc., Orchard Therapeutics, Gilead Lifesciences, Inc., Benitec Biopharma Ltd., Sibiono GeneTech Co., Ltd. and others

Market Segmentation
• By Gene Type
◦ Antigen
◦ Cytokine
◦ Tumor Suppressor
◦ Deficiency
◦ Growth Factors
◦ Receptors
◦ Other Gene Types

• By Delivery Method
◦ In Vivo gene therapy
◦ Ex Vivo gene therapy
• By Vector Type
◦ Viral Vector
▪ Retrovirus
▪ Lentivirus
▪ Adenovirus
▪ Adeno-associated Virus
▪ Herpes Simplex Virus
▪ Poxvirus
▪ Vaccinia Virus
▪ Other Viral Vectors
◦ Nonviral Vector
▪ Naked/Plasmid Vector
▪ Gene Gun
▪ Electroporation
▪ Lipofection
▪ Other Nonviral Vectors

• By Application
◦ Acute Lymphoblastic Leukemia (ALL)
◦ Inherited Retinal Disease
◦ Large B-Cell Lymphoma
◦ Melanoma (lesions)
◦ Beta-Thalassemia Major/SCD
◦ Head & Neck Squamous Cell Carcinoma
◦ Peripheral Arterial Disease
◦ Spinal Muscular Atrophy (SMA)
◦ Other Diseases

• Route of Administration

• Intraarticular
• Intracerebral
• Intracoronary
• Intradermal
• Intralesional
• Intramuscular
• Intrapleural
• Intrathecal
• Intratumoral
• Intravenous
• Intravesical
• Intravitreal
• Subretinal
• Topical
• Others

• By Region
◦ North America (U.S., Canada, Mexico)
◦ Europe (Germany, France, Italy, Spain, UK, Rest of Europe)
◦ Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific)
◦ Latin America (Brazil, Argentina, Rest of LAMEA)
◦ Middle East & Africa (Saudi Arabia, UAE, Bahrain, South Africa, Rest of MEA)